Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-16 | Elicera Therapeutics | Elicera Therapeutics publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Elicera Therapeutics | Elicera Therapeutics publishes the annual report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Elicera Therapeutics | Kallelse till årsstämma i Elicera Therapeutics AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Elicera Therapeutics | Elicera Therapeutics: Nomination committee proposes CMC specialist to Elicera's board of directors | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Elicera Therapeutics | Elicera Therapeutics valberedning föreslår CMC specialist till styrelsen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | Elicera Therapeutics | Elicera Therapeutics meddelar sista dag för handel i BTU och första dag för handel i teckningsoptioner serie TO2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | Elicera Therapeutics | Elicera Therapeutics announces the last day of trading in BTU and the first day of trading in warrants of series TO2 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Elicera Therapeutics announces the last day of trading in BTU and the first day of trading in warrants of series TO2Elicera Therapeutics AB (publ) (”Elicera” or ”the Company”) announces that the rights issue which the board of directors resolved on January 18, 2024 and was approved at the extraordinary general meeting on February 20, 2024 (”the Rights Issue”) has been registered with the Swedish Companies Registration Office (Bolagsverket). Trading of paid subscribed units (”BTU”) will therefore cease, and BTU will be replaced by shares and the warrants of series TO2. The last day of trading with BTU is March 28, 2024, and the warrants of series TO2 will be listed for trading on Nasdaq First North Growth Market on April 5, 2024. In connection with the registration with the Swedish Companies Registration Office, BTU are converted into newly issued shares and warrants of series TO2 with the ticker ELIC TO2. The first day of trading in the warrants of series TO2 on Nasdaq First North Growth Market is April 5, 2024. The last day of trading in warrants of series TO2 is March 6, 2025. Warrants of series TO2 Each warrant of series TO2 entitles the holder to subscribe for one (1) new share in the Company. The subscription price for subscription of shares with the support of warrants of series TO2 corresponds to 70 percent of the volume-weighted average price paid for the Company’s shares during the period from February 11, 2025, up to and including February 24, 2025, but not less than SEK 1.24 and not more than SEK 2.70. The exercise period for subscription of shares with the support of the warrants of series TO2 shall be made, in accordance with the terms of the warrants of series TO2, during the period from February 26, 2025, to March 11, 2025. The complete terms for the warrants of series TO2 are available on Elicera’s website, www.elicera.com. For more information, please contact: Jamal El-Mosleh, CEO at Elicera Therapeutics AB Mail: Phone: +46 (0) 703 31 90 51 Webb: www.elicera.com ( https://www.elicera.com/sv/home ) Certified Adviser The Company’s Certified Adviser is Carnegie Investment Bank AB (publ). The information was submitted for publication distributed through the contact person below at 14;01 CET on March 25, 2024. Advisers Mangold Fondkommission AB is the financial advisor to Elicera in connection with the Rights Issue. Advokatfirman Delphi i Stockholm AB is the legal advisor to the Company in connection with the Rights Issue. About Elicera Therapeutics AB Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. The company’s certified advisor is Carnegie Investment Bank AB (publ), www.carnegie.se. For additional information, visit www.elicera.com. Important information This press release is not an offer to sell shares or a solicitation of an offer to acquire securities of the Company. The contents of this press release have been prepared by the Company and the Company is solely responsible for its contents. The information in this press release is for background purposes only and therefore does not claim to be complete. No one should, for whatever reason, rely on the information contained in this press release or on its accuracy or completeness. The offer to subscribe for or acquire securities referred to in this press release is made through the EU growth prospectus provided by the Company, which contains detailed information about the Company. This press release constitutes an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with the related delegated and implementing regulations, the ”Prospectus Regulation”). Investors should not invest in the securities referred to in this press release without having taken into account the information contained in the aforementioned EU growth prospectus. The securities referred to in this press release have not been and will not be registered under the U.S. Securities Act as amended (the ”Securities Act”) and thus cannot be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act or the securities laws of the relevant state. The Company does not intend to register any offering in the United States or to make any offer of securities in the United States. This press release will not be distributed within, and should not be sent to, the United States. The securities described herein have also not been, and will not be, registered under the applicable securities laws of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction in which the distribution of this press release would be unlawful or require additional measures other than those required by Swedish law and may not, subject to certain exceptions, be offered or sell within or into, or for the benefit of, any person whose registered address is in or who is located or resident in, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea. There will be no offering of the securities described herein in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea. In the United Kingdom, this press release may only be distributed and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Financial Promotion Order” as amended), (ii) persons falling within Article 49 (2) (a) to (d) (”high net worth companies; unincorporated associations etc.”) of the Financial Promotion Order, (iii) persons that are outside the United Kingdom, or (iv) are persons to whom an invitation or incentive to engage in investment activities (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (”FSMA”)) in connection with the issue or sale of securities (all such persons together being referred to as ”relevant persons”). This press release is only directed at relevant persons and persons who are not relevant persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this communication relates is only possible for relevant persons and will only be pursued with relevant persons. In all EEA Member States (”EEA”), other than Sweden, this communication is only addressed to and is only directed at qualified investors in the relevant Member State as defined in the Prospectus Regulation, i.e. only those investors to whom an offer may be made without an approved prospectus in the relevant EEA Member State. Topics covered in this press release may contain forward-looking statements. Such statements are all statements that are not historical facts and contain expressions such as ”intends”, ”expects”, ”may”, ”plans”, ”estimates”, ”calculates” and other similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that these assumptions were reasonable when made, such forward-looking statements are subject to known and unknown risks, uncertainties, coincidences, and other important factors that are difficult or impossible to predict and that are beyond the Company’s control. Such risks, uncertainties and important factors could cause actual results to differ materially from those expressed or implied in this communication by the forward-looking statements. The information, opinions and forward-looking statements contained in this release speak only as of the date of this press release and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or release publicly any adjusted view of the forward-looking statements in order to reflect such events or circumstances that arise in relation to the content of these communications. |
||||
2024-03-22 | Elicera Therapeutics | Elicera Therapeutics AB byter Certified Adviser och Likviditetsgarant till Mangold Fondkommission AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-22 | Elicera Therapeutics | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-11 | Elicera Therapeutics | Elicera Therapeutics announces outcome in rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-11 | Elicera Therapeutics | Elicera Therapeutics offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera collaborates with US cancer centre to evaluate iTANK | Pressreleaser | Visa Stäng |
|
||||
2024-03-07 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera i samarbete med cancercenter i USA för utvärdering av iTANK | Pressreleaser | Visa Stäng |
|
||||
2024-03-06 | Elicera Therapeutics | Elicera Therapeutics: Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | Elicera Therapeutics | Elicera Therapeutics: Elicera ingår avtal med framstående amerikanskt cancercenter för att utvärdera användningen av iTANK i T-cellsreceptorterapier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics presenteras på Life Sciencedagen i Göteborg den 6 mars | Pressreleaser | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics erhåller utökade teckningsåtaganden från styrelse och ledning i den pågående företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Last day of trading in unit rights in Elicera Therapeutics rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Sista dag för handel med uniträtter i Elicera Therapeutics företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Emission ska ta Eliceras ELC-301 igenom klinisk studie | Pressreleaser | Visa Stäng |
|
||||
2024-02-27 | Elicera Therapeutics | Elicera Therapeutics: Eliceras vd till BioStock: "Den viktigaste händelsen sedan Eliceras start | Pressreleaser | Visa Stäng |
|
||||
2024-02-26 | Penser Future by Carnegie | Penser Future by Carnegie: Intervju med Elicera Therapeutics- Carnegie Investment Bank - 26 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-23 | Elicera Therapeutics | The subscription period in Elicera Therapeutics' rights issue of units starts today | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Elicera Therapeutics | Teckningsperioden i Elicera Therapeutics företrädesemission av units inleds idag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Elicera Therapeutics | Elicera Therapeutics publishes prospectus in connection with rights issue of units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Elicera Therapeutics | Elicera Therapeutics offentliggör prospekt i samband med företrädesemission av units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-20 | Elicera Therapeutics | Kommuniké från extra bolagsstämma i Elicera Therapeutics AB (publ) den 20 februari 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-19 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Full speed ahead for Elicera in 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-19 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Full fart framåt för Elicera under 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics abstract om iTANK-plattformens potential att förstärka CAR T-cellbehandling av solida tumörer accepterad för presentation på ISCT 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics: Elicera invites to investor meetings on February 28[th] and 29[th] 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics: Elicera bjuder in till investerarträffar 28 och 29 februari 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera får grönt ljus för klinisk CAR T-studie | Pressreleaser | Visa Stäng |
|
||||
2024-02-14 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera gets green light for CAR T clinical study | Pressreleaser | Visa Stäng |
|
||||
2024-02-14 | Penser Future by Carnegie | Penser Future by Carnegie: Elicera Therapeutics - Grönt ljus från Läkemedelsverket | Pressreleaser | Visa Stäng |
|
||||
2024-02-13 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Year-End Report 1 January - 31 December 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Elicera Therapeutics | Elicera Therapeutics erhåller godkännande att initiera den kliniska fas I/II-studien CARMA med CAR T-cellsterapin ELC-301 i B-cellslymfom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Elicera Therapeutics | Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | KALLELSE TILL extra bolagsSTÄMMA I Elicera Therapeutics AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: Elicera's Board of Directors proposes a rights issue of units of approximately SEK 64 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: Eliceras styrelse föreslår en företrädesemission av units om cirka 64 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-17 | Elicera Therapeutics | Elicera Therapeutics medgrundare Magnus Essand inbjuden att presentera bolagets CAR T-cellsprojekt vid världens största konferens om cancerimmunterapi, CICON | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-17 | Elicera Therapeutics | Elicera Therapeutics' co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-09 | Elicera Therapeutics | Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-09 | Elicera Therapeutics | Elicera Therapeutics deltar i ett samarbetsprojekt för utveckling av förbättrad CAR T-cellstillverkning som tilldelats forskningsstöd om 850 TSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics medgrundare får anslag på totalt 4,8 MSEK från Barncancerfonden för att stödja CAR T-forskning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics lämnar in GMP-valideringsdata till Läkemedelsverket för CARMA-studien i syfte att komplettera den villkorat godkända kliniska prövningsansökan | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Elicera Therapeutics | Elicera Therapeutics: BioStock: FDA CAR T investigation does not affect Elicera | Pressreleaser | Visa Stäng |
|
||||
2023-12-21 | Elicera Therapeutics | Elicera Therapeutics: BioStock: FDA:s CAR T-utredning påverkar inte Elicera | Pressreleaser | Visa Stäng |
|
||||
2023-11-30 | Elicera Therapeutics | Elicera Therapeutics AB byter Certified Adviser och Likviditetsgarant till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Elicera Therapeutics | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: CAR T deal puts spotlight on Elicera's technology | Pressreleaser | Visa Stäng |
|
||||
2023-11-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: CAR T-affär sätter fokus på Eliceras teknik | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera's CEO: " iTANK has great potential in treating solid tumours" | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Eliceras vd: "iTANK har hög potential vid behandling av solida tumörer" | Pressreleaser | Visa Stäng |
|
||||
2023-11-15 | Penser Future | Penser Future: Närmar sig en rad viktiga värdehöjande milstolpar - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Elicera Therapeutics | Elicera Therapeutics: Nomination Committee for Elicera therapeutics appointed | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Elicera Therapeutics | Elicera Therapeutics utser valberedning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Elicera Therapeutics | Elicera Therapeutics presenterar på BioStock Life Science Summit den 26 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | Elicera Therapeutics | Elicera Therapeutics får besked om beviljande av kinesiskt patent som skyddar iTANK-plattformen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-08 | Elicera Therapeutics | Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-30 | Penser Future | Penser Future: I väntan på studiestart - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-08-29 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 30 juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-15 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera's potential in cancer therapy published in Nature Communications | Pressreleaser | Visa Stäng |
|
||||
2023-08-15 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Eliceras potential inom cancerterapi publicerad i Nature Communications | Pressreleaser | Visa Stäng |
|
||||
2023-08-10 | Elicera Therapeutics | Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-10 | Elicera Therapeutics | Elicera Therapeutics publicerar en vetenskaplig artikel i Nature Communications om CAR T-konstruktionen i ELC-401 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-13 | Elicera Therapeutics | BioStock: Elicera Therapeutics säkrar viktigt EU-patent | Pressreleaser | Visa Stäng |
|
||||
2023-07-13 | Elicera Therapeutics | BioStock: Elicera Therapeutics receives important EU patent | Pressreleaser | Visa Stäng |
|
||||
2023-07-11 | Elicera Therapeutics | Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-11 | Elicera Therapeutics | Elicera Therapeutics får besked om beviljande av europeiskt patent som skyddar iTANK[TM]-plattformen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-30 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera gives an update in Cancer Immunotherapy Month | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera uppdaterar i samband med Cancer Immunotherapy Month | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Elicera Therapeutics | BioStock Life Science Spring Summit med Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Elicera Therapeutics | BioStock Life Science Spring Summit with Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Välfinansierat Elicera beredda för klinik och affärsutveckling | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Well-financed Elicera prepared for clinic and business development | Pressreleaser | Visa Stäng |
|
||||
2023-05-17 | Penser Future | Penser Future: Väl rustad för pågående och planerade kliniska studier - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Kommuniké från årsstämma i Elicera Therapeutics AB (publ) den 16 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-15 | Penser Future | Penser Future: Intervju med Elicera Therapeutics - Erik Penser Bank - 15 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-10 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Janssens CAR T-avtal ger stöd till Eliceras vision | Pressreleaser | Visa Stäng |
|
||||
2023-05-10 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Janssen CAR T deal supports Elicera's vision | Pressreleaser | Visa Stäng |
|
||||
2023-05-09 | Elicera Therapeutics | BioStock Studio: Elicera Therapeutics om Läkemedelsverkets villkorade godkännande | Pressreleaser | Visa Stäng |
|